Cranberry Research Today is a free monthly online journal that collates and summarizes the latest research about Cranberry, including details on benefits, antioxidants, utis, cystitis.

The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections.

Ball P

School of Biomedical Sciences, St Andrews University, St Andrews, Fife, UK.

By the 1960s and 1970s, problems in the antibacterial treatment of infections had begun to emerge. Previously active antibacterials were being compromised by the development of resistance. Beta-lactamase production was identified in isolates of staphylococci, and, amongst others, in Escherichia coli, Proteus mirabilis, Haemophilus influenzae and Moraxella catarrhalis. The discovery of the potent beta-lactamase inhibitor clavulanic acid, and its protective effect on amoxicillin, a semi-synthetic penicillin with good oral absorption and potent broad-spectrum antimicrobial activity, was thus of great importance in the treatment of bacterial disease. Following preliminary clinical studies in bronchitis and urinary tract infections, amoxicillin/clavulanate therapy was investigated in a wide range of infections and proved to demonstrate a high level of clinical efficacy. These results supported the launch of amoxicillin/clavulanate (Augmentin) in 1981 for use in upper and lower respiratory tract infections, urinary tract infections, skin and soft tissue infections and obstetric, gynaecological and intra-abdominal infections.

Published 20 November 2007 in Int J Antimicrob Agents, 30: 113-7.
Full-text of this article is available online (may require subscription).

© 2004-2008 Cranberry Research Today. All Rights Reserved.